ASCO 2026: Gilead CMO Dietmar Berger discusses the company's cell therapy and antibody-drug conjugate approaches in oncology, and shares the rationale on four recent acquisitions
- 2 minutes ago
- 1 min read
On the ADC front, he discusses Trodelvy's role in triple-negative breast cancer and the rationale for acquiring Tubulis for its next generation ADC pipeline. Plus, BCMA CAR-T (the acquisition of Arcellx), treating glioblastoma with CAR-T, and the future of in vivo cell therapy.






.png)
